AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
• Current targeted therapies benefit only a subset of patients, highlighting the need for novel treatment strategies.
• Metabolic reprogramming is a hallmark of cancer, providing energy and building blocks for tumor growth.

Purpose of the Study:

• To investigate the role of aldo-keto reductase family 1 member C1 (AKR1C1) in NSCLC proliferation.
• To elucidate the mechanisms by which AKR1C1 influences cancer cell metabolism.
• To explore AKR1C1 as a potential therapeutic target for NSCLC.

Main Methods:

• Loss- and gain-of-function experiments were employed to assess AKR1C1's impact on NSCLC cells.
• Molecular profiling analyses were conducted to examine gene expression changes.
• Correlation analyses were performed between AKR1C1, hypoxia-inducible factor 1-alpha (HIF-1α), and patient prognosis.

Main Results:

• Highly expressed AKR1C1 was found to accelerate NSCLC cell proliferation through metabolic reprogramming.
• AKR1C1 was shown to upregulate the expression of HIF-1α, a key regulator of tumor metabolism.
• A significant correlation between AKR1C1 expression and HIF-1α signaling was observed, predicting poor NSCLC patient prognosis.

Conclusions:

• AKR1C1 promotes NSCLC proliferation by reprogramming tumor metabolism via activation of HIF-1α.
• These findings establish AKR1C1's role in metabolic reprogramming and suggest its potential as a novel therapeutic target for NSCLC.